Disease · MONDO_0018905

diffuse large B-cell lymphoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. diffuse large B-cell lymphoma. Diseases, record MONDO_0018905. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018905

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: diffuse large B-cell lymphoma; Open Targets
Open Targets ID: MONDO_0018905; Open Targets
Other names: DLBCL; Open Targets
Disease Ontology: DOID:0050745; Disease Ontology
MeSH: D016403; MeSH
NCI Thesaurus: C8851; NCI Thesaurus
Orphanet: ORPHA:544; Orphanet
Highest stage of its drugs: Approval, for 10 of its 301 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs301

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
POLATUZUMAB VEDOTIN	CHEMBL3301582	Antibody drug conjugate	Approval	DailyMed, FDA, PMDA and TTD	69	64	61	Drugs and targets
GLOFITAMAB	CHEMBL4298092	Antibody	Approval	EMA Human Drugs, FDA and TTD	39	36	36	Drugs and targets
TAFASITAMAB	CHEMBL4298047	Antibody	Approval	ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA and TTD	29	24	24	Drugs and targets
SELINEXOR	CHEMBL3545185	Small molecule	Approval	DailyMed	21	19	16	Drugs and targets
EPCORITAMAB	CHEMBL4650393	Antibody	Approval	EMA Human Drugs, FDA and TTD	21	17	17	Drugs and targets
LONCASTUXIMAB TESIRINE	CHEMBL4297778	Antibody drug conjugate	Approval	EMA Human Drugs, FDA and TTD	19	16	16	Drugs and targets
TISAGENLECLEUCEL	CHEMBL3301574	Cell	Approval	EMA Human Drugs	14	10	10	Drugs and targets
AXICABTAGENE CILOLEUCEL	CHEMBL3989989	Gene	Approval	EMA Human Drugs and TTD	10	8	8	Drugs and targets
LISOCABTAGENE MARALEUCEL	CHEMBL4297236	Gene	Approval	EMA Human Drugs	8	7	7	Drugs and targets
OCRELIZUMAB	CHEMBL2108041	Antibody	Approval	TTD	1	0	0	Drugs and targets

1 to 10 of 301

See all 301 drugs

Targets368

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
MS4A1	B-lymphocyte antigen CD20	12	B-lymphocyte antigen CD20 binding agent	Approval	https://conductscience.org/library/genes/931	Drugs and targets
PDCD1	Programmed cell death protein 1	12	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
PIK3CD	PI3-kinase class I	11	PI3-kinase class I inhibitor; PI3-kinase p110-delta subunit inhibitor	Phase 2/3	https://conductscience.org/library/genes/5293	Drugs and targets
TUBA1A	Tubulin	10	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	10	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	10	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	10	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	10	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	10	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	10	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/203068	Drugs and targets

1 to 10 of 368

See all 368 targets

Trials889

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 10 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01287741	A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)	Phase 3	1,418	2017-08-17	Diffuse Large B-Cell Lymphoma	CYCLOPHOSPHAMIDE, DOXORUBICIN, OBINUTUZUMAB, PREDNISONE, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT01855750	A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma	Phase 3	838	2019-03-19	Lymphoma	CYCLOPHOSPHAMIDE, DOXORUBICIN, IBRUTINIB, PREDNISONE, RITUXIMAB, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00486759	A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma	Phase 3	787	2012-12-31	B-cell Lymphoma	BEVACIZUMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT01724021	A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a	Phase 3	743	2016-08-29	Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00790036	Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy	Phase 3	742	2017-07-12	Diffuse Large B-cell Lymphoma	EVEROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT01649856	A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma	Phase 3	572	2016-02-12	Lymphoma, Large B-Cell, Diffuse	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT02285062	Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma	Phase 3	570	2020-03-30	Lymphoma, Large B-Cell, Diffuse	CYCLOPHOSPHAMIDE, DOXORUBICIN, LENALIDOMIDE, PREDNISONE, RITUXIMAB, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00118209	Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma	Phase 3	524	2020-04-17	Large B Cell Lymphoma	CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, PREDNISONE, RITUXIMAB, VINCRISTINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT02763319	A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)	Phase 2/3	453	2025-07-17	Diffuse Large B-cell Lymphoma	BENDAMUSTINE, TAFASITAMAB	Its record names the disease	ClinicalTrials.gov
NCT00719472	A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)	Phase 3	451	2012-06-26	Non-Hodgkin's Lymphoma	RITUXIMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 889

See all 889 trials

Comparisons in its trials154

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy: serious adverse events	269 of 701	312 of 702	1,403	NCT01287741	Trial comparisons
Treatment Arm B: Ibrutinib+R-CHOP vs Treatment Arm A: Placebo+R-CHOP: deaths from any cause	78 of 416	78 of 418	834	NCT01855750	Trial comparisons
Treatment Arm B: Ibrutinib+R-CHOP vs Treatment Arm A: Placebo+R-CHOP: serious adverse events	221 of 416	143 of 418	834	NCT01855750	Trial comparisons
Bevacizumab + Rituximab + CHOP vs Placebo + Rituximab + CHOP: serious adverse events	224 of 395	173 of 386	781	NCT00486759	Trial comparisons
Arm A vs Arm B: Number of Participants With Treatment Emergent Adverse Events (AEs)	352 of 371	347 of 369	740	NCT01724021	Trial comparisons
Arm A vs Arm B: serious adverse events	126 of 371	116 of 369	740	NCT01724021	Trial comparisons
Rituximab SC vs Rituximab IV: serious adverse events	155 of 369	77 of 203	572	NCT01649856	Trial comparisons
Lenalidomide Plus R-CHOP (R2-CHOP) vs Placebo Plus R-CHOP: deaths from any cause	85 of 285	88 of 285	570	NCT02285062	Trial comparisons
Lenalidomide Plus R-CHOP (R2-CHOP) vs Placebo Plus R-CHOP: serious adverse events	104 of 283	88 of 284	567	NCT02285062	Trial comparisons
Rituximab SC vs Rituximab IV: Number of Participants With an Event-Free Survival (EFS) Event	116 of 342	53 of 177	519	NCT01649856	Trial comparisons

1 to 10 of 154

See all 154 comparisons in its trials

Papers from its trials515

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41428995	RESULT	1	PubMed
40802906	RESULT	4	PubMed
38889737	RESULT	1	PubMed
38837078	RESULT	1	PubMed
37157906	RESULT	1	PubMed
36548927	RESULT	1	PubMed
36375046	RESULT	1	PubMed
34779360	RESULT	1	PubMed
34196165	RESULT	1	PubMed
32511983	RESULT	1	PubMed

1 to 10 of 515

See all 515 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0018905

GET https://conductscience.org/api/diseases/v1/MONDO_0018905/drugs?page=2

API reference For AI assistants